| Hemophilia A
Altuviiio vs Afstyla
Side-by-side clinical, coverage, and cost comparison for hemophilia a.Deep comparison between: Altuviiio vs Afstyla with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAfstyla has a higher rate of injection site reactions vs Altuviiio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Afstyla but not Altuviiio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Altuviiio
Afstyla
At A Glance
IV infusion
Once weekly
Recombinant factor VIII
IV infusion
2-3 times weekly
Recombinant Factor VIII
Indications
- Hemophilia A
- Hemophilia A
Dosing
Hemophilia A - Routine Prophylaxis 50 IU/kg IV once weekly for adults and children.
Hemophilia A - On-demand (Minor and Moderate Bleeding) Single dose of 50 IU/kg IV; a lower dose of 30 IU/kg may be used for bleeds occurring within 2 to 3 days after a prophylactic dose; additional doses of 30 or 50 IU/kg every 2 to 3 days may be considered.
Hemophilia A - On-demand (Major Bleeding) Single dose of 50 IU/kg IV; additional doses of 30 or 50 IU/kg every 2 to 3 days may be considered.
Hemophilia A - Perioperative (Minor Surgery) Pre-operative: single dose of 50 IU/kg IV; post-operative: an additional dose of 30 or 50 IU/kg after 2 to 3 days may be considered.
Hemophilia A - Perioperative (Major Surgery) Pre-operative: single dose of 50 IU/kg IV; post-operative: additional doses of 30 or 50 IU/kg every 2 to 3 days as clinically needed.
Hemophilia A - On-demand treatment and control of bleeding Target Factor VIII activity 20-40 IU/dL for minor bleeds, 30-60 IU/dL for moderate bleeds, and 60-100 IU/dL for major/life-threatening bleeds; repeat IV injection every 8-24 hours until bleeding is resolved. Dose (IU) = body weight (kg) x desired Factor VIII rise (IU/dL) x 0.5.
Hemophilia A - Routine prophylaxis Adults and adolescents (>=12 years): 20-50 IU/kg IV 2-3 times weekly; children may require more frequent dosing based on pharmacokinetic data and individual response.
Hemophilia A - Perioperative management Target 30-60 IU/dL for minor surgery (repeat every 24 hours for >=1 day); target 80-100 IU/dL for major surgery (repeat every 8-24 hours until adequate wound healing, then maintain 30-60 IU/dL for >=7 more days) via IV injection.
Contraindications
- Severe hypersensitivity reactions, including anaphylaxis, to ALTUVIIIO or any of its excipients
- Life-threatening hypersensitivity reactions, including anaphylaxis, to AFSTYLA or any excipient (e.g., polysorbate 80) or to hamster proteins
Adverse Reactions
Most common (>10%) Headache, arthralgia (adults and adolescents); pyrexia (children below 12 years)
Serious Thromboembolic events (1% of patients in long-term extension, in patients with pre-existing risk factors)
Postmarketing Factor VIII inhibitor development, hypersensitivity reactions including anaphylaxis
Most common (>0.5%) Factor VIII inhibition (in previously untreated patients), hypersensitivity, dizziness
Postmarketing Factor VIII inhibitor development
Pharmacology
Recombinant FVIII Fc-VWF-XTEN fusion protein that temporarily replaces missing coagulation factor VIII to restore hemostasis in hemophilia A; half-life is extended 3- to 4-fold over standard FVIII products through Fc-FcRn recycling, VWF D'D3 domain shielding from endogenous VWF, and XTEN-mediated reduction in clearance.
AFSTYLA is a recombinant single-chain Factor VIII with a truncated B-domain and covalent linkage between heavy and light chains that replaces missing Coagulation Factor VIII needed for effective hemostasis; it exhibits higher VWF affinity relative to full-length rFVIII, providing increased molecular stability and protection from degradation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Altuviiio
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Afstyla
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Altuviiio
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Afstyla
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Altuviiio
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Afstyla
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AltuviiioView full Altuviiio profile
AfstylaView full Afstyla profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.